It is not known if donor-recipient ABO blood group incompatibility contributes to graft-versus-leukemia after allogeneic BMT. One hundred and nineteen patients with acute myeloid leukemia in first remission underwent non-T cell-depleted marrow allografts from HLA-identical siblings after TBI and cyclophosphamide (n ‫؍‬ 72) or melphalan (n ‫؍‬ 47). GVHD prophylaxis comprised cyclosporine alone or cyclosporine-methotrexate. Twenty-two patients relapsed at 3-46 months (median 7): 18 of 76 patients with ABO-matched donors and four of 43 patients with ABO-mismatched donors (actuarial 5-year probabilities 33 ؎ 6% vs 12 ؎ 6%; P ‫؍‬ 0.028). The incidence of acute and chronic GVHD was not affected by ABO mismatch. The following factors were studied in Cox analysis for effect on outcome: gender, age, FAB subtype, ABO mismatch, CR-transplant interval, conditioning, TBI dose, nucleated cell dose, lymphocyte recovery, acute GVHD, and chronic GVHD. Donor-recipient ABO match was the only factor independently associated with a higher risk of relapse (RR ‫؍‬ 3.7; 95% Cl, 1.1-12.6; P ‫؍‬ 0.04). ABO mismatch was also associated with superior overall and disease-free survivals. We conclude that ABO incompatibility may influence relapse rates and survival favorably after allogeneic BMT. It is not known if this holds true for allogeneic blood stem cell transplants.
Immunologically mediated graft-versus-leukemia (GVL) reactions reduce relapse after allogeneic bone marrow transplantation (BMT). [1] [2] [3] Enhanced GVL reactions and reduced relapse rates are seen after allogeneic peripheral blood stem cell transplantation (PBSCT) 4, 5 possibly due to the higher number of infused T cells and rapid immune reconstitution. The relevance of ABO blood groups to allogeneic transplantation has been thought to be confined to cell processing (plasma and/or red cell depletion) and transfusion. [6] [7] [8] A detrimental effect of donor-recipient ABO incompatibility on outcome has been suggested by some groups 9, 10 but not others. [11] [12] [13] [14] [15] In an analysis of the long-term outcome of 85 adults and children with acute myeloid leukemia (AML) who underwent allogeneic BMT in the first complete remission (CR) after cyclophosphamide and total-body irradiation (TBI), we found that donor-recipient ABO incompatibility was associated with a lower risk of relapse. 16 We now examine the influence of ABO incompatibility on the outcome of a larger number of adult AML patients allografted in first CR.
Patients and methods
The database of the Leukaemia Unit of the Royal Marsden Hospital was searched to obtain information on 119 consecutive AML patients allografted in first CR using marrow from HLA-identical siblings who fulfilled the following criteria: age у16 years, conditioning regimen cyclophosphamide-TBI or melphalan-TBI, no T cell depletion, cyclosporine as graft-versus-host disease (GVHD) prophylaxis (with methotrexate in case of melphalan-TBI conditioning). Cyclophosphamide-TBI transplants were performed between August 1978 and November 1986 (n ϭ 72; included in the previous report 16 , and melphalan-TBI between February 1989 and October 1999 (n ϭ 47)). Patients conditioned with melphalan-TBI between 1981 and 1988 received cyclosporine alone as GVHD prophylaxis. These patients had a very high treatment-related mortality (Ͼ50%) 17, 18 and a very low relapse rate (Ͻ3%), 17, 19 and have been excluded from this analysis. PBSCT recipients were excluded because of the lower risk of relapse. 4, 5 All research protocols were approved by the local institutional review board, and all patients and donors gave informed consent for transplant and harvest. Patient characteristics are shown in Table 1 .
Conditioning regimens
Cyclophosphamide was administered in two divided doses of 60 mg/kg (actual body weight) on days Ϫ3 and Ϫ2. Melphalan was administered as a single dose of 110 mg/m 2 (actual body weight) on day Ϫ1. Single-fraction TBI (950 or 1050 cGy) was delivered from opposed 60 Co sources at a low rate (4 cGy/min) on day 0. seven cyclophosphamide-TBI recipients received 1150 cGy TBI.
Donor marrow
Marrow was harvested from the iliac crests under general anesthesia on day 0. The target cell quantity was 2 ϫ 10 8 nucleated cells/kg (actual patient weight). The marrow was not depleted of T cells, and was infused into the patient unmanipulated except as required for ABO incompatibility. 14 When the donor and recipient had the same ABO blood group, donor marrow was infused unmanipulated. With minor ABO incompatibility (donor possessing isohemagglutinins against recipient red cells), the marrow was depleted of plasma. This group included the following blood group combinations: O (donor) into A, B or AB (recipient), and A or B (donor) into AB (recipient). With major ABO incompatibility (recipient possessing isohemagglutinins against donor red cells), the marrow was depleted of red cells, and, between 1979 and 1984, patients underwent plasma exchanges to reduce the titer of lytic antibodies. This group included the following blood group combinations: A, B or AB (donor) into O (recipient), and AB (donor) into A or B (recipient). With bidirectional ABO incompatibility (both donor and recipient possessing isohemagglutinins to each other; A into B and vice versa), the marrow was depleted of both red cells and plasma.
GVHD prophylaxis
Before intravenous cyclosporine became available, the drug was administered intramuscularly at the dose of 25 mg/kg from day Ϫ1 for 5 days, and then orally at a dose of 12.5 mg/kg. After intravenous cyclosporine became available, the drug was administered intravenously at the dose of 3 mg/kg from day Ϫ1 until oral intake was resumed. It was then given orally at the dose of 12.5 mg/kg until day 50, after which it was tapered slowly, and was discontinued by 6-8 months post transplant.
Methotrexate was administered at the dose of 15 mg/m 2 on day 1, and 10 mg/m 2 on days 3, 6 and 11. The dose was not altered unless required by significantly altered renal or hepatic function. Specifically, the day 11 dose was never omitted on account of mucositis.
Acute GVHD was usually diagnosed and graded on the basis of clinical findings, and was treated with conventional-(2 mg/kg) or high-(10-20 mg/kg) dose corticosteroids. Symptomatic chronic GVHD was treated with cyclosporine, prednisolone, azathioprine, and thalidomide in varying combinations.
Transfusions
Recipients of major ABO-incompatible allografts received recipient or O type packed red cells, whereas recipients of minor or bidirectional ABO-incompatible allografts received type O packed red cells. All other blood products were of donor origin (or AB) after major ABO-incompatible grafts, recipient origin (or AB) after minor ABOincompatible grafts, and of AB type after bidirectional ABO-incompatible grafts. When O group platelets were used for A, B or AB group recipients, plasma was depleted.
Other supportive care
All patients were treated in protective isolation in rooms with positive-pressure ventilation. Blood products transfused then were not screened for cytomegalovirus (CMV) antibody until the late 1980s when screening was instituted for CMV-seronegative patient-donor pairs. Neutropenic fever was treated with broad-spectrum antibiotics and amphotericin as necessary.
Statistical methods
Data were analyzed as of August 2001, when the median follow-up duration of the survivors was 9 years. Groups were compared using the Wilcoxon rank-sum test for continuous variables or the 2 test for categoric variables. The actuarial probabilities of transplant-related mortality (TRM), relapse, and event-free survival (EFS) were calculated according to the method of Kaplan and Meier. For estimating EFS, patients were censored at the last followup, and relapse or death due to treatment-related mortality were plotted as failures. Two patients dying 2 and 10 years after BMT from clearly unrelated causes (complications of surgery and ischemic heart disease, respectively) were censored at the time of death for all four outcomes. Both patients had donors who were ABO-matched.
The following variables, the choice of which was based upon our previous experience, 8, [16] [17] [18] 20 were analyzed for their effect on the probabilities of TRM, relapse, EFS, and overall survival (OS). Gender, age (р35 vs Ͼ35 years), FAB type (M1-3 vs M0, 4-7 vs unknown), CR-BMT interval (р120 vs Ͼ120 days), TBI dose (950 vs Ͼ950 cGy), conditioning regimen (cyclophosphamide-TBI vs melphalan-TBI), donor-patient ABO blood group compatibility (match vs mismatch), the nucleated cell dose infused (р2.6 vs Ͼ2.6 ϫ 10 8 /kg), the absolute lymphocyte count (ALC) on day 29 (Ͻ0.2 vs у0.2 ϫ 10 9 /l vs not available), and development of acute or chronic GVHD (yes vs no).
Karyotype was not available in a number of patients who were sent to us for transplantation after having been treated elsewhere. CMV serology information was missing in a number of patients transplanted before the importance of CMV became obvious. These factors were not considered in the analysis.
Univariate analyses were carried out using Kaplan-Meier plots and log-rank test. All factors were entered into a stepwise multivariable analysis based on Cox's proportional hazards model to determine which factors independently influenced the probabilities of TRM, relapse, EFS and OS.
Results
The recipients of ABO-matched and mismatched grafts were comparable (Table 1 ). There was a trend towards ABO-matched recipients being younger. The incidence of acute or chronic GVHD was not influenced by ABO incompatibility.
Bone Marrow Transplantation Thirty-eight patients died of treatment-related causes at 3 weeks to 123 months (median 3.5 months). The actuarial 5-year probability of TRM (Ϯ s.e.) was 31 Ϯ 4%. Twentytwo patients relapsed 3 to 46 months (median 7) after BMT. The actuarial 5-year probability of relapse was 25 Ϯ 5%. Twenty-one died of disease or toxicity of further therapy, 15 and one is alive in second CR 7 years after relapse following chemotherapy and G-CSF-mobilized donor leukocytes. 21, 22 Sixty-one patients are alive in CR (60 in continuous first CR and one in second CR) at 1 to 22.3 years (median 9.1). The actuarial 5-year probabilities of EFS and OS were 51 Ϯ 5% and 53 Ϯ 5%, respectively. Table 2 shows the effect of the various factors on outcome in univariate analysis. TRM was adversely affected by advanced age and acute GVHD. Relapse was adversely affected by donor-recipient ABO match. Figures 1 and 2 show the impact of donor-recipient ABO incompatibility on relapse and EFS. There were trends for higher relapse rates with FAB types M0, 4-7, cyclophosphamide-TBI conditioning, and no acute GVHD.
The significance of the relapse difference resulting from ABO mismatch was maintained when stratified by the con- ditioning regimen (P ϭ 0.03) and the occurrence of acute GVHD (P ϭ 0.05) (details not shown). The effect of ABO incompatibility on relapse stratified by FAB type, the only biologic variable affecting prognosis in AML analyzed here, is shown in Figure 3 . The beneficial effect of ABO incompatibility seemed more marked amongst patients with higher risk disease. The effect of ABO incompatibility on relapse stratified by the day 29 ALC, a variable shown by us to affect relapse rates in the past, 20 is shown in Figure 4 . The beneficial effect of ABO incompatibility seemed more marked amongst patients with better lymphocyte recovery. Table 3 shows the outcome of ABO matched, minor ABO mismatched (this includes bidirectional mismatches; see Donor marrow under Patients and methods), and major ABO mismatched transplants. While none of the differences are significant because of small numbers, it appears that the outcome of major ABO-mismatched BMT is closer to minor ABO-mismatched BMT than to ABO-matched BMT.
As Table 4 shows, ABO incompatibility was found to affect all the measures of outcome favorably. Advanced age increased TRM, affecting EFS and OS adversely. The development of acute GVHD increased TRM significantly. Melphalan-TBI conditioning was associated with superior EFS and OS.
Discussion
Our data show that the outcome of patients with AML allografted in first CR from HLA-identical siblings is better due to reduced relapse if the donor is ABO-mismatched. This observation needs confirmation. It is not known if this holds true for different clinical circumstances.
Data on the effect of ABO-matching on the outcome of BMT are limited and conflicting. Five reports have found no deleterious effects of ABO mismatch. [11] [12] [13] [14] [15] However, Benjamin et al. 9 reported poorer survival after allografts The effect of donor-recipient ABO incompatibility on relapse rates stratified by the day 29 absolute lymphocyte count (overall P ϭ 0.06). from ABO-incompatible donors. This was due to unusual local transfusion practices (infusion of large quantities of O group plasma to A, B and AB group recipients with platelet concentrates). Its modification made the outcome of ABOmatched and mismatched BMT equivalent. 23 Stussi et al 10 found that bidirectional ABO incompatibility was associated with significantly higher TRM compared with ABO compatibility. There were only six patients in the bidirectional mismatch group, and the outcome of major and minor mismatched patients was similar to that of ABOmatched patients. In a study examining the relationship between donorrecipient ABO incompatibility and post-transplant jaundice in 477 patients, we could detect no effect of ABO incompatibility on TRM, relapse or survival. 14 The heterogeneity of diagnoses, stage and conditioning regimens could have obscured any effect of ABO mismatch on relapse, but probably not on TRM. Therefore, the balance of evidence indicates that ABO incompatibility is not a risk factor for increased complications or mortality following BMT. In a study of 174 patients with aplastic anemia or leukemia, Bacigalupo et al 24 found that minor ABO incompatibility was associated with a significantly higher risk of severe acute GVHD compared with ABO-matched and major ABO-mismatched pairs. The cumulative incidence of grade II-IV acute GVHD was 39%, 54%, and 82% for ABO major-mismatched, matched, and minor-mismatched pairs (P ϭ 0.01). This observation makes sense because of the graft-versus-host direction of the immunologic reactions involved. The effect of this on outcome (relapse or survival) was not studied. Kalaycioglu et al 25 found that relapse risk in acute and chronic leukemia patients was significantly lower after major ABO-incompatible BMT compared to ABO-compatible BMT with no difference in GVHD. This seemed difficult to explain because the recipients contained hemagglutinins to the donor red cells in this mismatch setting (hostversus-graft reactions rather than graft-versus-host). When we initially made the observation of lower relapse with ABO mismatch, 16 the effect of minor vs major mismatch could not be analyzed fully due to small patient numbers. With a larger group of patients, we find that major ABO mismatch appears to behave like minor ABO mismatch rather than ABO match (Table 3) .
Why should ABO mismatch affect relapse rates? It is possible that the immune reactions associated with ABOmismatched transplants may have direct anti-leukemic effects or may enhance GVL through cytokine effects. Transfusions can result in increased cytotoxic and helper T lymphocyte precursor numbers 26 which, after allogeneic BMT, could augment GVL. Another potential mechanism operating here could be NK cell-mediated cell lysis directed against carbohydrate ABO blood groups. 27 The day 29 ALC, which affects relapse, TRM and survival in our experience, 20 did not affect the outcome here in Cox analysis (although there was an effect in univariate analysis), possibly because of smaller patient numbers. The previous study was performed in a larger group of patients with variable conditioning regimens and GVHD prophylaxis (including T cell depletion).
Further work is necessary to determine the effects of ABO incompatibility on the outcome of allogeneic BMT. Even if ABO mismatch is found to be associated with decreased relapse, the information would have to be interpreted in the context of the widespread shift to the use of allogeneic PBSCT which is associated with a lower risk of relapse. 4, 5 We do not have enough data to comment on the effects of ABO-incompatibility on relapse after PBSCT.
Until the issue is explored further, what are the practical implications of these findings? ABO compatibility is an issue only if there are two HLA-identical sibling donors who are otherwise equivalent. Our current algorithm in choosing a donor is to look for CMV seronegativity (for CMV-seronegative patients), followed by male sex, young age, and then ABO mismatch. If our findings are not substantiated, ABO-matched donors would be preferable because of transfusion issues.
